Deal-Making
Syncona bids $28m to progress Gaucher disease gene therapy
Deal MakingSyncona bids $28m to progress Gaucher disease gene therapySyncona bids $28m to progress Gaucher disease gene therapy
Syncona will acquire Freeline Therapeutics to aid development of adeno-associated virus (AAV) gene therapy candidate FLT201.